The top of Dana-Farber Most cancers Institute has introduced her plans to step down, as her successor has been appointed to guide the world-renowned most cancers heart.
Laurie Glimcher will step down as president and CEO on Oct. 1, and she is going to assume the title of president emerita.
Glimcher has additionally served as director of the Dana-Farber/Harvard Most cancers Middle, and is the Richard and Susan Smith professor of Medication at Harvard Medical College.
The seventh president of Dana-Farber and the primary lady to guide the group in its 77-year historical past, Glimcher started her tenure in October 2016. Dana-Farber is credited for taking part in a essential position within the growth of 51% of all most cancers medication permitted by the FDA over the previous 5 years.
“Eight years ago, I began this journey with a deep appreciation for the extraordinary research that emanated from Dana-Farber since its earliest days and the clinical excellence that Dana-Farber provides patients and families,” stated Glimcher. “And now, as I reflect on my tenure, I am intensely proud of what we have achieved in providing world class care for our patients, leading in innovation, and discovering new treatments and cures.”
Beneath Glimcher’s management, the Institute’s regional areas grew from 4 to seven, there was a 51% development in affected person quantity and a 62% improve in grant and industry-funded analysis assist, totaling $450 million in FY23.
Final 12 months, she introduced Dana-Farber’s proposal to construct a brand new 300-bed inpatient hospital devoted to grownup sufferers with most cancers and a brand new collaboration with Beth Israel Deaconess Medical Middle.
Glimcher will stay at Dana-Farber, the place she is going to proceed each her analysis and her involvement in mentoring the subsequent era of physician-scientists, together with different particular tasks.
In the meantime, Benjamin Ebert, chair of the Division of Medical Oncology, has been named as the subsequent president and CEO of Dana-Farber.
“I’m extraordinarily honored to be selected as the next president and CEO of Dana-Farber and to build on the exceptional leadership and accomplishments of Laurie Glimcher,” stated Ebert. “Dana-Farber is truly a remarkable organization and a global leader in innovation, and in caring and advocating for cancer patients. Together with our executive leadership team, I will continue to advance a patient-first model as we open this new chapter.”
Initially Revealed:
